{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055598","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.704665+00:00","generated_at":"2026-06-02T09:45:21.785626+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CytomX Q1 revenue $41.5M, up 77% YoY; positive early CX-904 data","bullets":["Q1 revenue $41.5M vs $23.5M YoY; cash $150.3M at Mar 31, 2024.","CX-904 (EGFRxCD3) shows favorable safety; 2 of 6 pancreatic patients with confirmed partial responses.","CX-2051 (EpCAM ADC) first patient dosed Apr 2024; first dose cohort cleared; initial data H1 2025.","CX-801 (IFNα2b) to start Phase 1 in Q2 2024; collaboration with Merck for KEYTRUDA combo.","Achieved $10M in Astellas milestones for two T-cell engager programs; Dr. Zhen Su appointed to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055598","json":"https://secwatch.observer/filing/0000950170-24-055598.json","markdown":"https://secwatch.observer/filing/0000950170-24-055598.md","text":"https://secwatch.observer/filing/0000950170-24-055598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/0000950170-24-055598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/ctmx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:45:21.785626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"853756d227f9fb4017cca72682799e8b1c429782","claim":"CytomX Therapeutics, Inc. reported financial results for first quarter 2024.","evidence_excerpt":"On May 8, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/0000950170-24-055598-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}